RxDoctor Payments Data

Sarah Beucher, MD

Family Medicine · Rock Valley, IANPI 1265834618

Payments from drug & device makers

$4,694in general payments, 2019–2025

Across 239 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$716
  • Lilly USA, LLC$665
  • Amgen$637
  • AbbVie$427
  • Pfizer$283
  • GSK$276
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,54997%
  • Education$1453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,694 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$13,593
Medicare patients
58
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide124$133,109
OzempicSemaglutide100$118,937
EliquisApixaban119$66,463
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$55,709
TrulicityDulaglutide42$47,717
JanuviaSitagliptin Phosphate28$28,471
LinzessLinaclotide18$17,225
JardianceEmpagliflozin19$15,913
XareltoRivaroxaban20$9,961
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,716
Repatha SureclickEvolocumab11$6,096
MyrbetriqMirabegron18$4,574
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$4,550
Potassium Chloride155$4,468
Atorvastatin Calcium301$3,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$665$180,826166 claims
Novo NordiskOzempic$716$118,937100 claims
PfizerEliquis$283$66,463119 claims
GSKTrelegy Ellipta$276$55,70940 claims
MerckJanuvia$187$28,47128 claims
AbbVieLinzess, Synthroid$427$18,62530 claims
Boehringer IngelheimJardiance$113$15,91319 claims
Johnson & JohnsonXarelto$69$9,96120 claims
AstraZenecaBreztri Aerosphere$108$7,71612 claims
Astellas Pharma US IncMyrbetriq$164$4,57418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Rock Valley

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →